ATE273956T1 - Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten - Google Patents

Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten

Info

Publication number: ATE273956T1
Authority: AT; Austria
Prior art keywords: amine; methyl; penten; pyridyl; aryl
Prior art date: 1998-06-16

Application number

AT99926152T

Other languages

English (en)

Inventor

William Scott Caldwell

Gary Maurice Dull

Balwinder Singh Bhatti

Srishailkumar B Hadimani

Haeil Park

Jared Miller Wagner

Peter Anthony Crooks

Patrick Michael Lippiello

Merouane Bencherif

Original Assignee

Targacept Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-16

Filing date

1999-06-03

Publication date

2004-09-15

1998-06-16 Priority claimed from US09/098,133 external-priority patent/US6232316B1/en

1999-06-03 Application filed by Targacept Inc filed Critical Targacept Inc

2004-09-15 Application granted granted Critical

2004-09-15 Publication of ATE273956T1 publication Critical patent/ATE273956T1/de

Links

108010009685 Cholinergic Receptors Proteins 0.000 title 1
102000034337 acetylcholine receptors Human genes 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
KETAPARGUJRPEI-HWKANZROSA-N (e)-5-(5-bromopyridin-3-yl)-n-methylpent-4-en-2-amine Chemical compound CNC(C)C\C=C\C1=CN=CC(Br)=C1 KETAPARGUJRPEI-HWKANZROSA-N 0.000 abstract 1
KJZMFQZAEDAMAE-FNORWQNLSA-N (e)-5-(5-ethoxypyridin-3-yl)-n-methylpent-4-en-2-amine Chemical compound CCOC1=CN=CC(\C=C\CC(C)NC)=C1 KJZMFQZAEDAMAE-FNORWQNLSA-N 0.000 abstract 1
HXZJTUDXVFHWOB-GQCTYLIASA-N (e)-5-(5-methoxypyridin-3-yl)-n-methylpent-4-en-2-amine Chemical compound CNC(C)C\C=C\C1=CN=CC(OC)=C1 HXZJTUDXVFHWOB-GQCTYLIASA-N 0.000 abstract 1
RPCVIAXDAUMJJP-FNORWQNLSA-N (e)-n-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine Chemical compound CNC(C)C\C=C\C1=CN=CC(OC(C)C)=C1 RPCVIAXDAUMJJP-FNORWQNLSA-N 0.000 abstract 1
IEVJOUFGBRDCNE-ZZXKWVIFSA-N (e)-n-methyl-5-pyridin-3-ylpent-4-en-2-amine Chemical compound CNC(C)C\C=C\C1=CC=CN=C1 IEVJOUFGBRDCNE-ZZXKWVIFSA-N 0.000 abstract 1
VZNTWLIIJWUCEP-HWKANZROSA-N (e)-n-methyl-5-pyrimidin-5-ylpent-4-en-2-amine Chemical compound CNC(C)C\C=C\C1=CN=CN=C1 VZNTWLIIJWUCEP-HWKANZROSA-N 0.000 abstract 1
RPCVIAXDAUMJJP-HOSRBBHYSA-N (e,2r)-n-methyl-5-(5-propan-2-yloxypyridin-3-yl)pent-4-en-2-amine Chemical compound CN[C@H](C)C\C=C\C1=CN=CC(OC(C)C)=C1 RPCVIAXDAUMJJP-HOSRBBHYSA-N 0.000 abstract 1
IEVJOUFGBRDCNE-QLCVYAKKSA-N (e,2r)-n-methyl-5-pyridin-3-ylpent-4-en-2-amine Chemical compound CN[C@H](C)C\C=C\C1=CC=CN=C1 IEVJOUFGBRDCNE-QLCVYAKKSA-N 0.000 abstract 1
IEVJOUFGBRDCNE-YVGDHZEHSA-N (e,2s)-n-methyl-5-pyridin-3-ylpent-4-en-2-amine Chemical compound CN[C@@H](C)C\C=C\C1=CC=CN=C1 IEVJOUFGBRDCNE-YVGDHZEHSA-N 0.000 abstract 1
XDXHBRXUPFIIRK-GQCTYLIASA-N 3-methyl-5-[(e)-4-(methylamino)pent-1-enyl]pyridin-2-amine Chemical compound CNC(C)C\C=C\C1=CN=C(N)C(C)=C1 XDXHBRXUPFIIRK-GQCTYLIASA-N 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
RPCVIAXDAUMJJP-PZBABLGHSA-N ispronicline Chemical compound CN[C@@H](C)C\C=C\C1=CN=CC(OC(C)C)=C1 RPCVIAXDAUMJJP-PZBABLGHSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compounds Of Unknown Constitution (AREA)
Cosmetics (AREA)

AT99926152T 1998-06-16 1999-06-03 Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten ATE273956T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9828598A	1998-06-16	1998-06-16
US09/098,133 US6232316B1 (en)	1998-06-16	1998-06-16	Methods for treatment of CNS disorders
PCT/US1999/012340 WO1999065876A1 (en)	1998-06-16	1999-06-03	Aryl substituted olefinic amines and their use as cholinergic receptors agonists

Publications (1)

Publication Number	Publication Date
ATE273956T1 true ATE273956T1 (de)	2004-09-15

Family

ID=26794206

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99926152T ATE273956T1 (de)	1998-06-16	1999-06-03	Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten

Country Status (12)

Country	Link
EP (1)	EP1086082B9 (de)
JP (4)	JP4240815B2 (de)
KR (1)	KR100593433B1 (de)
AT (1)	ATE273956T1 (de)
AU (1)	AU4230799A (de)
BR (1)	BR9911325A (de)
CA (3)	CA2677519A1 (de)
DE (1)	DE69919537T2 (de)
DK (1)	DK1086082T3 (de)
ES (1)	ES2228054T3 (de)
PT (1)	PT1086082E (de)
WO (1)	WO1999065876A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6979695B2 (en) *	1996-04-23	2005-12-27	Targacept, Inc.	Compounds capable of activating cholinergic receptors
CA2677519A1 (en) *	1998-06-16	1999-12-23	Targacept, Inc.	Aryl substituted olefinic amines and their use as cholinergic receptors agonists
JP2003501416A (ja) *	1999-06-07	2003-01-14	ターガセプト，インコーポレイテッド	医薬組成物およびその使用法
EP1212301A1 (de) *	1999-08-31	2002-06-12	Targacept, Inc.	Arylalkyloxyalkylamine und arylalkylthioalkylamine, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als inhibitoren von nikotin cholinergen rezeptoren
AU2001257449A1 (en) *	2000-05-01	2001-11-12	Targacept, Inc.	Imaging of nicotinic acetylcholine receptor subtypes
US6432954B1 (en) *	2000-07-14	2002-08-13	Targacept, Inc.	Pharmaceutical compositions and methods for use
EP1463481A4 (de)	2001-12-14	2008-06-25	Targacept Inc	Verfahren und zusammensetzungen zur behandlung von erkrankungen des zentralen nervensystems
US8580842B2 (en)	2003-09-30	2013-11-12	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
AU2004282201A1 (en)	2003-10-15	2005-04-28	Targacept, Inc.	Azabicycyclic compounds for relieving pain and treating central nervous system disorders
US7459469B2 (en)	2004-11-10	2008-12-02	Targacept, Inc.	Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) *	2004-11-10	2009-11-25	Таргасепт, Інк.	Гидроксибензоатные соли метаникотиновых соединений
TWI389889B (zh)	2006-05-09	2013-03-21	Targacept Inc	（２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
US8017785B2 (en)	2006-05-09	2011-09-13	Astrazeneca Ab	Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
US20100234349A1 (en)	2006-09-04	2010-09-16	Olsen Gunnar M	Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US20080167286A1 (en)	2006-12-12	2008-07-10	Abbott Laboratories	Pharmaceutical compositions and their methods of use
US8486979B2 (en)	2006-12-12	2013-07-16	Abbvie Inc.	1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es)	2006-12-30	2008-07-31	Abbott Gmbh & Amp	Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
KR20100052490A (ko) *	2007-07-31	2010-05-19	타가셉트 인코포레이티드	(2ｓ)-(4ｅ)-ｎ-메틸-5-(3-(5-이소프로폭시피리딘)일)-4-펜텐-2-아민의 경피투여
WO2010009775A1 (de)	2007-12-07	2010-01-28	Abbott Gmbh & Co. Kg	Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
EP2231644B1 (de)	2007-12-07	2014-01-15	AbbVie Deutschland GmbH & Co KG	5,6-Disubstitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
KR20100097195A (ko)	2007-12-07	2010-09-02	애보트 게엠베하 운트 콤파니 카게	５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
JP5701607B2 (ja)	2007-12-07	2015-04-15	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
US8383657B2 (en)	2007-12-21	2013-02-26	Abbott Laboratories	Thiazolylidine urea and amide derivatives and methods of use thereof
WO2009146031A1 (en)	2008-03-31	2009-12-03	University Of South Florida	Methods of treating disease-induced ataxia and non-ataxic imbalance
EP2435080A2 (de)	2009-05-29	2012-04-04	Abbott Laboratories	Pharmazeutische zusammensetzungen zur schmerzbehandlung
US8703802B2 (en) *	2010-05-20	2014-04-22	Targacept, Inc.	Process for the preparation of aryl substituted olefinic amines
WO2013184732A1 (en) *	2012-06-06	2013-12-12	Targacept, Inc.	Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5242935A (en) *	1992-03-06	1993-09-07	R. J. Reynolds Tobacco Company	Method for treatment of neurodegenerative diseases
US5597716A (en) *	1993-11-18	1997-01-28	Mitsubishi Rayon Co., Ltd.	Process for producing D-lactic acid and L-lactamide
US5597919A (en) *	1995-01-06	1997-01-28	Dull; Gary M.	Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616707A (en) *	1995-01-06	1997-04-01	Crooks; Peter A.	Compounds which are useful for prevention and treatment of central nervous system disorders
AU4610896A (en) *	1995-01-06	1996-07-24	R.J. Reynolds Tobacco Company	Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5585388A (en) *	1995-04-07	1996-12-17	Sibia Neurosciences, Inc.	Substituted pyridines useful as modulators of acetylcholine receptors
AU5383196A (en) *	1995-05-17	1996-11-29	R.J. Reynolds Tobacco Company	Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5616716A (en) *	1996-01-06	1997-04-01	Dull; Gary M.	(3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
JP4357001B2 (ja) *	1996-04-23	2009-11-04	ターガセプト，インコーポレイテッド	中枢神経系障害の予防及び治療のための医薬組成物
US5629325A (en) *	1996-06-06	1997-05-13	Abbott Laboratories	3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
AU749151B2 (en) *	1997-02-21	2002-06-20	Targacept, Inc.	Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
CA2677519A1 (en) *	1998-06-16	1999-12-23	Targacept, Inc.	Aryl substituted olefinic amines and their use as cholinergic receptors agonists

1999
- 1999-06-03 CA CA002677519A patent/CA2677519A1/en not_active Abandoned
- 1999-06-03 DK DK99926152T patent/DK1086082T3/da active
- 1999-06-03 AU AU42307/99A patent/AU4230799A/en not_active Abandoned
- 1999-06-03 PT PT99926152T patent/PT1086082E/pt unknown
- 1999-06-03 KR KR1020007014279A patent/KR100593433B1/ko not_active Expired - Fee Related
- 1999-06-03 ES ES99926152T patent/ES2228054T3/es not_active Expired - Lifetime
- 1999-06-03 CA CA2709735A patent/CA2709735A1/en not_active Abandoned
- 1999-06-03 EP EP99926152A patent/EP1086082B9/de not_active Expired - Lifetime
- 1999-06-03 DE DE69919537T patent/DE69919537T2/de not_active Expired - Lifetime
- 1999-06-03 BR BR9911325-2A patent/BR9911325A/pt not_active Application Discontinuation
- 1999-06-03 WO PCT/US1999/012340 patent/WO1999065876A1/en not_active Ceased
- 1999-06-03 CA CA002334923A patent/CA2334923C/en not_active Expired - Fee Related
- 1999-06-03 JP JP2000554703A patent/JP4240815B2/ja not_active Expired - Fee Related
- 1999-06-03 AT AT99926152T patent/ATE273956T1/de active
2008
- 2008-05-19 JP JP2008130502A patent/JP4972608B2/ja not_active Expired - Fee Related
- 2008-05-19 JP JP2008130504A patent/JP4896923B2/ja not_active Expired - Fee Related
2010
- 2010-06-15 JP JP2010135746A patent/JP2010229149A/ja active Pending

Also Published As

Publication number	Publication date
DE69919537D1 (de)	2004-09-23
EP1086082B9 (de)	2005-03-02
AU4230799A (en)	2000-01-05
KR20010083052A (ko)	2001-08-31
CA2334923A1 (en)	1999-12-23
JP4972608B2 (ja)	2012-07-11
JP2002518373A (ja)	2002-06-25
JP4896923B2 (ja)	2012-03-14
JP2010229149A (ja)	2010-10-14
DK1086082T3 (da)	2004-11-22
EP1086082A1 (de)	2001-03-28
BR9911325A (pt)	2001-04-03
DE69919537T2 (de)	2005-09-08
JP4240815B2 (ja)	2009-03-18
CA2677519A1 (en)	1999-12-23
CA2334923C (en)	2009-09-29
PT1086082E (pt)	2005-01-31
CA2709735A1 (en)	1999-12-23
EP1086082B1 (de)	2004-08-18
ES2228054T3 (es)	2005-04-01
KR100593433B1 (ko)	2006-06-28
WO1999065876A1 (en)	1999-12-23
JP2008260774A (ja)	2008-10-30
JP2008255122A (ja)	2008-10-23

Legal Events

Date

Code

Title

Description

2005-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1086082

Country of ref document: EP

Publication	Publication Date	Title
ATE273956T1 (de)	2004-09-15	Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
BR9810342A (pt)	2000-09-05	Novos compostos imidazola substituìdos
TR200300322T2 (tr)	2003-09-22	Kemokin alıcısını bağlayan heterosiklik bileşikler
DE60008133D1 (de)	2004-03-11	Farbstoff-markierte imidazochinolinverbindungen
PT935465E (pt)	2004-08-31	Compostos novos de imidazole substituido
TR200102029T2 (tr)	2001-11-21	1-Heterosiklil ikameli diarilaminler.
TR200000782T2 (tr)	2000-09-21	Resorsinol türevleri.
BR9913221B1 (pt)	2008-11-18	composiÇço catalisadora suportada de metaloceno.
ATE247470T1 (de)	2003-09-15	Neue substituierte imidazolverbindungen
DE69917296D1 (de)	2004-06-17	Neue substituierte triazolverbindungen
ID23374A (id)	2000-04-20	Halogenopirimidin
AU9102198A (en)	1998-11-27	Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
DE69832200D1 (de)	2005-12-08	2,3-substituierte indolverbindungen als cox-2 inhibitoren
TR200103276T2 (tr)	2002-05-21	Yeterince yağsız siklosporin kompozisyonları
PT998460E (pt)	2004-07-30	Novos derivados de tetrazole
DE60020595D1 (de)	2005-07-07	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
TR200002896T2 (tr)	2001-01-22	Kalsilitik Bileşimler
TR200003390T2 (tr)	2001-03-21	2-(2-Metilfenil)-3,4-dihidro-2H-pirol türevleri
ATE387448T1 (de)	2008-03-15	4,5-pyrazinoxindole als proteinkinasehemmer
TR200003389T2 (tr)	2001-02-21	2-(2-klorofenil)-3,4-dihidro-2H-pirol türevleri.
EA199800867A1 (ru)	1999-02-25	Соединения тетрагидробетакарболина
ATE281439T1 (de)	2004-11-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE251457T1 (de)	2003-10-15	Substituierte 1,2,3,4-tetrahydro-2- dibenzofuranamine und 2- aminocyclohepta(b)benzofurane
DE60319989D1 (de)	2008-05-08	Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande
ES2166045T3 (es)	2002-04-01	Procedimiento para la preparacion de compuestos de 4,6-bis(ariloxi)pirimidina asimetricos.